Abstract: The eyeglass frame is an improved eyeglass frame with dislocating joints. The dislocating joints prevent damage to the eyeglass frame when external forces are applied to the structure and allow for the frame to be disconnected, if so desired. The joints dislocate without completely separating from the other components of the eyeglass frame or becoming damaged, and the joints can be quickly reconnected without tools.

Abstract: Methods of targeting atherosclerotic plaques using LyP-1 related peptides are provided. In some embodiments, the methods include administering a peptide comprising a LyP peptide to an animal, wherein the peptide homes to an atherosclerotic plaque, thereby targeting the atherosclerotic plaque. Also provided are methods for ameliorating a sign or symptom associated with an inflammatory condition using LyP-1 related peptides.

Abstract: According to the embodiments described herein, a methods for inhibiting small ubiquitin-like modifier enzymes in a cell are provided. Such methods may include administering certain substituted pyrrolo[2,3-b]-quinoxalines to the cell. In some aspects, the small ubiquitin-like modifier enzyme is SUMO E1 or SUMO E2. In some aspects, the methods may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, methods for treating a cancer, degenerative diseases and viral infection are provided. Such methods may include administering an effective amount of a pharmaceutical composition to a subject having cancer. The pharmaceutical composition may include a small ubiquitin-like modifier inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.

Abstract: A method and system for determining a position of a source including obtaining prompt data and related delayed data from a Positron Emission Tomography (PET) scanner, generating a sinogram from the prompt data, generating crystal efficiency correction factors by performing a normalization calibration based on the obtained delayed data, performing normalization correction on the generated sinogram based on the crystal efficiency correction factors to generate a corrected sinogram, rebinning the corrected sinogram to generate a plurality of two-dimensional sinogram slices, and determining a central axis for each of the plurality of two-dimensional sinogram slices using a center estimation process.

Abstract: Provided herein are compositions and methods for selectively targeting an endometriosis cell.

Abstract: The invention relates to methods and assays for the detection of active Alternative Lengthening of Telomeres (ALT) activity in cells. The methods and assays involve detecting or assaying for partially double-stranded telomeric circles wherein the presence of said circles is specific for cells comprising an active ALT mechanism. In some embodiments the methods find application in, inter alia, determining the level of ALT activity in a cell, determining the ALT status of a cancer in a subject, diagnosing and/or treating disease, determining disease status, analysis of treatment efficacy, and the identification of novel therapeutic agents.

Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimetic thereof.

Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.

Abstract: Disclosed herein are Furin/PC inhibitors for inhibiting Furin and other Propprotein Convertases. Method of making the Furin/PC inhibitors, chemical and biological characterization of the Furin/PC inhibitors, and the use of the Furin/PC inhibitors to treat infectious diseases, cancers, and inflammatory/autoimmune disorders, are also disclosed.

Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.

Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.

Abstract: The present subject matter relates to methods and apparatus for using hyperpolarization to improve imaging. Am exemplary embodiment, a PASADENA polarizer, is capable of delivering 2.5-5 ml of highly hyperpolarized biological 13C and 15N imaging reagents in less than one minute, and capable of repeated delivery every 5-8 minutes. Exemplary quality control sequences are also provided to create versatile methods, systems, and apparatuses for a variety of biomolecules, capable of undergoing reaction with parahydrogen necessary for effective PASADENA. The subject matter simplifies the technology for routine liquid state generation of hyperpolarized molecules for 13C and 15N subsecond imaging and spectroscopy in vivo and further advance the clinical application of this technology. Methods and systems for providing magnetic shielding are also provided.

Abstract: The present invention relates to novel benzodiazepinone compounds of Formulae (I) wherein R1, R2, R4, R6, R7, R8, R9, and R10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions. The compounds are Group II metabotropic glutamate antagonists or allosteric modulators and are useful for the treatment of a variety of CNS disorders.

Abstract: The disclosure provides compounds and methods of using Apogossypolone derivatives for treating diseases and disorders. In particular, the disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and provides methods for the preparation of compounds of Formula I; and methods for treating cancer, autoimmune diseases, and inflammation by administering a compound of Formula I.

Abstract: Disclosed are compositions and methods related to clot-binding compounds. For example, disclosed are compositions comprising a surface molecule and at least one modified clot-binding compound. The modified clot-binding compound can selectively bind to clotted plasma protein, wherein the composition causes clotting and amplifies the accumulation of the composition in tumors. The modified clot-binding compound can enhance the clotting in tumors compared to its unmodified derivative. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.

Abstract: The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells.

Abstract: A positioning device is described for supporting the chest and head of a patient in a desired position during a medical procedure. The device includes removable inserts that allow the device to be adjusted to fit the size of the patient's head and torso.

Abstract: The present invention describes an apparatus, a systems and a method for the treatment of obstructive sleep apnea. the treatment involves monitoring the position of the tongue and/or the force exerted by the tongue an electrical stimulation of the hypoglossal nerve to move the tongue into an anterior position or to maintain the tongue in an anterior position.

Abstract: Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual.

Abstract: A sanitary disposable urine device is provided that includes an inner ring and outer ring each having a top surface and opposing bottom surface. The outer ring is substantially concentric with the inner ring and may be offset. At least one of the top surfaces of the inner and outer rings conforms to a body contour of a user's perineum. The device includes a hand holder coupled to the bottom surface of the inner ring, the hand holder having an opening configured to match to the inner ring. The device includes a fluid containing bag having an open end attached to the hand holder such that fluid flows through the inner ring and the opening of the hand holder into the fluid containing bag during usage. The device includes an inner bag inside the fluid containing bag having an absorbent material and an outer sealable bag to secure the device after use.